SEC FORM 3

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Llewelyn Linda

(Last)

(First)

(Middle)

C/O HEALTH CATALYST, INC.

3165 MILLROCK DRIVE, #400

(Street)

SALT LAKE CITY

84121

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
07/24/2019

3. Issuer Name and Ticker or Trading Symbol
Health Catalyst, Inc. [ HCAT ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief People Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (Right to Buy)	⁽¹⁾	08/28/2023	Common Stock	260	$4.42	D
Stock Option (Right to Buy)	⁽¹⁾	05/13/2024	Common Stock	500	$6.24	D
Stock Option (Right to Buy)	⁽²⁾	08/04/2025	Common Stock	1,000	$10.04	D
Stock Option (Right to Buy)	⁽³⁾	10/14/2026	Common Stock	3,750	$10.6	D
Stock Option (Right to Buy)	⁽⁴⁾	01/24/2028	Common Stock	19,999	$11.78	D
Stock Option (Right to Buy)	⁽⁵⁾	09/27/2028	Common Stock	75,000	$10.8	D

Explanation of Responses:

1. This stock option award is fully vested and exercisable.

2. 25% of the shares vested on June 1, 2016, and the remaining 75% vest in 36 equal monthly installments thereafter.

3. 25% of the shares vested on October 14, 2017, and the remaining 75% vest in 36 equal monthly installments thereafter.

4. 25% of the shares vested on January 24, 2019, and the remaining 75% vest in 36 equal monthly installments thereafter.

5. 25% of the shares shall vest on September 25, 2019; and the remaining 75% vest in 36 equal monthly installments thereafter.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Daniel Orenstein, as Attorney-in-Fact	07/24/2019
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.